AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$COR

Cencora: Fiscal Q4 Earnings Snapshot

Cencora, Inc. (COR) reported fiscal Q4 earnings of $519.4 million, or $2.71 per share, beating analyst expectations. Revenue was $88.35 billion, also exceeding forecasts. The company expects full-year earnings of $19.40 to $19.75 per share.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cencora: Fiscal Q4 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CORBullishHigh
01

Why it matters

The earnings beat may trigger short covering and buying interest, especially from investors focused on health‑care distribution.

02

Market read

First‑report earnings release with beat; high relevance for traders watching health‑care stocks.

03

What to watch

Potential headwinds from drug pricing pressures and payer reforms could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Cencora (formerly AmerisourceBergen) is a major prescription drug distributor reporting its fiscal Q4 results.

Company-level read

Ticker impact

$CORBullishHigh confidence
Context

Cencora reported Q4 earnings of $2.71 EPS, adjusted $4.66 EPS, and $88.35B revenue, beating estimates.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

Both headline EPS and revenue exceeded analyst expectations, indicating better-than-expected performance.

Market effects

Sector

Strong results may lift other pharmaceutical distributors and health‑care supply chain stocks.

Regional

Positive for U.S. health‑care sector indices.

Global

Limited to U.S. and global health‑care distribution outlook.

Counterpoint

What could challenge this read

If guidance falls short of expectations, the stock could face a pullback despite the beat.

Key entities

  • Company
    Cencora, Inc.

    Prescription drug distributor reporting Q4 earnings.

Read at source← All news

StoryCencora reports Q4 earnings beat and issues FY2027 EPS guidance

Also covered by

3 outlets

Related articles

NOV 4
$CORMed

Cencora, Inc. (COR): Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revised) (As Revised)

Cencora, Inc. (COR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue information for the periods indicated: Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter

SEC EDGAR 8-K2 min
NOV 4
$CORHighAI 9/10

Cencora beats estimates on earnings and revenue

Cencora Inc. (NYSE:COR) reported Q4 adjusted EPS of $4.66, beating estimates, with revenue at $88.4B, up 5.5% YoY. The company issued fiscal 2027 EPS guidance of $19.40-$19.75, above consensus. Shares dipped 0.07% in pre-market trading. Cencora also raised its dividend by 10% and reaffirmed long-term growth targets.

investing.com2 min
NOV 4
$CORHighAI 8/10

CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66 Fiscal Year 2026 Revenue of $337.4 Billion up 5.0 Percent. GAAP Diluted EPS of $

SEC EDGAR 8-K2 min